share_log

Capricor Therapeutics Analyst Ratings

Benzinga ·  Aug 15, 2023 18:35
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/15/2023 172.31% HC Wainwright & Co. → $18 Reiterates Buy → Buy
03/16/2023 172.31% HC Wainwright & Co. → $18 Reiterates → Buy
10/26/2022 126.93% Ladenburg Thalmann → $15 Initiates Coverage On → Buy
01/31/2022 172.31% HC Wainwright & Co. $14 → $18 Maintains Buy
10/11/2021 111.8% HC Wainwright & Co. $9 → $14 Maintains Buy
07/15/2019 87.59% HC Wainwright & Co. $3.5 → $12.4 Maintains Buy
12/31/2018 -47.05% HC Wainwright & Co. $8.6 → $3.5 Maintains Buy

What is the target price for Capricor Therapeutics (CAPR)?

The latest price target for Capricor Therapeutics (NASDAQ: CAPR) was reported by HC Wainwright & Co. on August 15, 2023. The analyst firm set a price target for $18.00 expecting CAPR to rise to within 12 months (a possible 172.31% upside). 3 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for Capricor Therapeutics (CAPR)?

The latest analyst rating for Capricor Therapeutics (NASDAQ: CAPR) was provided by HC Wainwright & Co., and Capricor Therapeutics reiterated their buy rating.

When is the next analyst rating going to be posted or updated for Capricor Therapeutics (CAPR)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Capricor Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Capricor Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.

Is the Analyst Rating Capricor Therapeutics (CAPR) correct?

While ratings are subjective and will change, the latest Capricor Therapeutics (CAPR) rating was a reiterated with a price target of $0.00 to $18.00. The current price Capricor Therapeutics (CAPR) is trading at is $6.61, which is within the analyst's predicted range.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment